Sage Therapeutics

Sage Therapeutics, founded in Cambridge, Massachusetts, focuses on developing treatments for central nervous system disorders. Their core mission is to transform the lives of patients by discovering and delivering novel therapies for conditions such as schizophrenia, major depressive disorder, pain, and traumatic brain injuries. Sage's flagship product, ZURZUVAE™ (zuranolone), is specifically designed for the treatment of postpartum depression, reflecting their commitment to addressing unmet medical needs.

Notable affiliated individuals include industry leaders and researchers dedicated to advancing neuropsychiatric care. The company has garnered significant investment from prominent venture capital firms, enabling robust research and development initiatives. Sage Therapeutics' key achievements include the successful launch of ZURZUVAE™, which has made a substantial impact on the lives of women suffering from postpartum depression. Their innovative approach continues to influence the field of neuropsychiatry, positioning them as a pivotal player in the biopharmaceutical industry.